MAGEA3 and neoplasm: Tumor-specific tetramer+ CD8 T cell responses reached averages of 39% for MelA (range 12–59%), 7.4% for GP100 (range 0.2–24%), 0.3% for TYR (range 0.05–1.2%) and 1.1% for MAGE-3 (range 0.1–4.3%) after 20 days with baseline levels format day 0 1.7, 0.2, 0.05 and 0.3%, respectively.